Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891901 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
A Phase 2 study of Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03891901 is a Phase 2 study of Tuberculosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 934-participant average among 29 other Tuberculosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03891901, a Phase 2 study of Tuberculosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and effects of imatinib on myelopoiesis in adults when given with and without isoniazid and rifabutin. The results of this trial will determine the imatinib dose to be studied in a subsequent Phase IIB treatment trial of imatinib as an adjunctive therapy with an antimicrobial regimen (rifabutin, pyrazinamide (PZA), isoniazid (INH) and ethambutol) for drug-sensitive TB.
Conditions Studied
Interventions
- DRUG Imatinib
- DRUG Rifabutin
- DRUG Isoniazid
Study Locations (1)
Georgia
- Emory University DAIDS TB Non-Network CRS - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891901
The ClinicalTrials.gov registry entry for NCT03891901 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 29 other Tuberculosis trials with a reported enrollment target (97% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 3 interventions - of which Imatinib is the first listed.
NCT03891901 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03891901 about?
NCT03891901 is a clinical study titled "A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin". The purpose of this study is to evaluate the safety, pharmacokinetics, and effects of imatinib on myelopoiesis in adults when given with and without isoniazid and rifabutin. The results of this trial will determine the imatinib dose to be studied in a subsequent Phase IIB treatment trial of imatinib...
What is the current status of trial NCT03891901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-10-27. Estimated completion is 2022-08-30.
What conditions does trial NCT03891901 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT03891901?
The interventions under investigation include: Imatinib (DRUG), Rifabutin (DRUG), Isoniazid (DRUG).
Who is sponsoring clinical trial NCT03891901?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03891901 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
COMPLETED · Phase 2
-
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
COMPLETED · Phase 2
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.